The early 1990s were in many ways the most terrible of those first years of the AIDS epidemic in America. Research on the disease was in high gear, but drug after drug failed to stop H.I.V. Funerals for friends and family in their 20s, 30s, 40s and 50s continued unabated, and many of us at risk for getting sick had given up hope of a normal life. My friends and I, most of us just a few years out of college, lived in the moment because we weren’t sure of how much time we had left.
My cousin Carl died from AIDS-related lymphoma in July 1995. That was also the year I found out that I, too, was H.I.V. positive. I wondered if Carl’s fate might be my own soon enough.
But then we got lucky. In 1996 a new generation of treatments called protease inhibitors emerged that were able to control H.I.V. Doctors talked about the Lazarus effect: watching their patients go from near death to health. I enrolled in a clinical trial and started taking the drugs that...
The U.S. government must move “quickly and decisively” to avert substantial national security risks stemming from artificial intelligence (AI) which could, in the worst case, cause an “extinction-level threat to the human species,” says a report commissioned by the U.S...
By Nada Hassanein, New Jersey Monitor | 03.14.2024
Aggregated News
The U.S. Food and Drug Administration late last year approved two breakthrough gene therapies for sickle cell disease patients. Now a new federal program seeks to make these life-changing treatments available to patients with low incomes — and it could...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.